Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Suicidal Thinking Health Advisory Limited To Lilly’s Strattera

Executive Summary

FDA does not intend to release a general public health advisory for attention deficit/hyperactivity disorder medications despite issuing one for Lilly's Strattera (atomoxetine) Sept. 29

You may also be interested in...



Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says

Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23

Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says

Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23

Suicidality Risk With ADHD Drugs Should Be Treated As Class Effect – Cmte.

The risk of suicidality in children receiving drugs to treat attention deficit/hyperactivity disorder should be viewed as a class effect, FDA's Pediatric Advisory Committee recommended March 22

Related Content

Topics

UsernamePublicRestriction

Register

PS046371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel